LoQus23 Therapeutics appoints Cyrus Mozayeni MD to Chair of the Board of Directors
- Dr Mozayeni brings deep experience in biotech corporate strategy and business development
- Appointment follows successful £35 million Series A fundraise at the end of 2024 to take its MSH3 inhibitors to treat Huntington’s disease into the clinic
Cambridge, UK, 18 February 2025 – LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause and driver of Huntington’s Disease, myotonic dystrophy type 1, and other triplet repeat expansion diseases, today announces the appointment of Dr Cyrus Mozayeni as its Chair of the Board of Directors.
